SDx Releases Autopsy-Confirmed Results for DISCERN™ Alzheimer’s Test and Physicians’ Assessment of Clinical Utility of DISCERN at BRAINWeek 2023

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), recently participated at BRAINWeek 2023 with the release of compelling data on the performance of the Morphometric Imaging (MI) assay of the DISCERN test and the results of a clinical utility study demonstrating the role of DISCERN in informed physician decision-making. DISCERN is an autopsy-validated, minimally invasive diagnostic skin test that assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD, as well as regulators of amyloid plaque and tau formation—hallmarks of AD at autopsy. 

Frank Amato, CEO and president, SDx, says, “Results from our autopsy-validated clinical study demonstrate that the MI assay accurately identified AD in people diagnosed with dementia, even in the presence of other co-morbid pathologies at autopsy.” 

Amato further explains the results support the conclusion that the MI assay accurately identifies AD, even in the presence of mixed dementia, adding, “Over 50% of people with AD also have other pathologies of dementia, the presence of which can complicate diagnosis with the current diagnostic pathway and may adversely impact treatment outcomes.” 

Read the full release here: https://tinyurl.com/3pxeubep